KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild-type stage III colon cancers from an adjuvant chemotherapy trial (N0147 alliance). - Wikidata - wikimedia - TriplyDB

KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild-type stage III colon cancers from an adjuvant chemotherapy trial (N0147 alliance).

KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild-type stage III colon cancers from an adjuvant chemotherapy trial (N0147 alliance).

http://www.wikidata.org/entity/Q33693309

about

Implications of mismatch repair-deficient status on management of early stage colorectal cancer Different treatment strategies and molecular features between right-sided and left-sided colon cancers RAS and BRAF in metastatic colorectal cancer management Analyses of clinicopathological, molecular, and prognostic associations of KRAS codon 61 and codon 146 mutations in colorectal cancer: cohort study and literature review.The prognostic significance of KRAS and BRAF mutation status in Korean colorectal cancer patients.Prognostic Impact of Deficient DNA Mismatch Repair and Mutations in KRAS, and BRAF(V600E) in Patients with Lymph Node-Positive Colon Cancer Colorectal carcinomas with KRAS codon 12 mutation are associated with more advanced tumor stages Distinct Clinicopathological Patterns of Mismatch Repair Status in Colorectal Cancer Stratified by KRAS Mutations.The Mutant KRAS Gene Up-regulates BCL-XL Protein via STAT3 to Confer Apoptosis Resistance That Is Reversed by BIM Protein Induction and BCL-XL Antagonism Factors Associated With Guideline-recommended KRAS Testing in Colorectal Cancer Patients: A Population-based Study.Analysis of Molecular Markers by Anatomic Tumor Site in Stage III Colon Carcinomas from Adjuvant Chemotherapy Trial NCCTG N0147 (Alliance)RAS signaling and anti-RAS therapy: lessons learned from genetically engineered mouse models, human cancer cells, and patient-related studies.Molecular pathological epidemiology of colorectal cancer in Chinese patients with KRAS and BRAF mutations Molecular Biomarkers in the Personalized Treatment of Colorectal Cancer.Prognostic Utility of Molecular Factors by Age at Diagnosis of Colorectal Cancer.Prognostic and predictive value of extended RAS mutation and mismatch repair status in stage III colorectal cancer TIMP-1 is under regulation of the EGF signaling axis and promotes an aggressive phenotype in KRAS-mutated colorectal cancer cells: a potential novel approach to the treatment of metastatic colorectal cancer.Association of DNA Mismatch Repair and Mutations in BRAF and KRAS With Survival After Recurrence in Stage III Colon Cancers : A Secondary Analysis of 2 Randomized Clinical Trials.Targeting EGFR in metastatic colorectal cancer beyond the limitations of KRAS status: alternative biomarkers and therapeutic strategies.Variation in KRAS driver substitution distributions between tumor types is determined by both mutation and natural selection.Prognostic Value of BRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer.Current and future biomarkers in the treatment of colorectal cancer.Specific mutations in KRAS codon 12 are associated with worse overall survival in patients with advanced and recurrent colorectal cancer.The prognostic implications of primary colorectal tumor location on recurrence and overall survival in patients undergoing resection for colorectal liver metastasis.What We Know About Stage II and III Colon Cancer: It's Still Not Enough.KRAS and Combined KRAS/TP53 Mutations in Locally Advanced Rectal Cancer are Independently Associated with Decreased Response to Neoadjuvant Therapy.Racial Differences in BRAF/KRAS Mutation Rates and Survival in Stage III Colon Cancer Patients.KRAS as a predictor of poor prognosis and benefit from postoperative FOLFOX chemotherapy in patients with stage II and III colorectal cancer Rapid and accurate detection of KRAS mutations in colorectal cancers using the isothermal-based optical sensor for companion diagnostics.Association between clinicopathological characteristics and RAS mutation in colorectal cancer.Benefit of Adjuvant Chemotherapy After Curative Resection of Lung Metastasis in Colorectal Cancer.[Molecular pathology of colorectal cancer].In silico-guided sequence modifications of K-ras epitopes improve immunological outcome against G12V and G13D mutant antigens Are Gene Signatures Ready for Use in the Selection of Patients for Adjuvant Treatment?New Development of Biomarkers for Gastrointestinal Cancers: From Neoplastic Cells to Tumor Microenvironment

P2860

Q26772272-6E242D13-D8CF-49FA-8426-1F61472F0EB8 Q26865322-5CCFBB03-E0F7-4538-B009-E1A9F819186C Q28074175-6A2F18F3-0A19-4843-8D26-B25F743BEE53 Q33732199-2FFE3A41-D4AA-4535-A189-648079ABC7BB Q33768220-B99ADB19-2654-4264-B6E4-73EE87130E17 Q34472453-567480CE-A20C-420B-AD6C-00B97BEEE467 Q35579056-9F7AB023-A322-4180-BE3A-56B93B636DD2 Q35652713-0FE9067B-C9FC-4B91-9723-4B92C2C4114E Q36092931-41E53828-57B5-4DD4-B4BA-98263E4DEA16 Q36113105-B2AEBC1E-3DD7-40B8-9766-16EE20104BC9 Q36342900-89333838-E30D-4CC5-A14D-595BC8DC1C05 Q36398735-8A5300A6-D6C7-415F-9A97-CA6D6B90C37E Q36545430-DC81C016-231E-4E8F-B1D6-469AF63F167A Q36813582-2AD42419-35AF-4C10-B13A-795D9610FB88 Q36954147-832B0EFD-3401-4CB9-9EDF-C2EB823E6E26 Q37098312-740A77CA-2AEB-4F19-88AA-102FF97D6285 Q37644878-8302E4C5-083A-4E18-84A0-51768195561E Q38383214-77CD8586-1B21-418D-989F-B45126A62029 Q38390840-CE69C584-705B-4612-B684-705EC99D0E9A Q38594037-E140D4EA-862E-4DF5-AE7C-BCEB837DF7F5 Q38775876-53714D0C-55B8-4BE9-AD9B-E342F2207E8C Q38787244-C0B0BBD6-0400-49AB-97A9-E94ABB8FAA7D Q39139086-25269084-7C96-4BF8-9CDE-47E9ADCC57D7 Q39238657-78080D55-F22F-4E0E-9676-73E96B905CF7 Q39306576-53C2D849-A820-43E0-B162-927B422E3E3B Q39884524-333D7DBD-4FE2-4FD5-AC39-090630EC1697 Q40752079-3664B467-BB1A-4D78-875F-B947BFDAABB6 Q41136513-295EDFD7-DA80-4846-81A7-E9CA622CDFCD Q47139907-7D582261-96D4-4160-9200-CDEB756114AB Q48010330-199E512A-2A7D-4226-89FA-4F8633245C1A Q52147418-57369DE2-54F1-47C1-9FDE-B8E6C85CC82C Q53581884-3F3C965B-C9AB-487D-A878-836C869F34FD Q57175287-F01B8379-6766-41E4-BD1A-6745CDAE6A00 Q58053523-DC41E80A-9C72-470D-9CF0-64486E712DE8 Q58783978-887EBC33-40AD-4F82-92B8-908476BF4A51

P2860

KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild-type stage III colon cancers from an adjuvant chemotherapy trial (N0147 alliance).

http://www.wikidata.org/entity/Q33693309

description

2014 nî lūn-bûn

@nan

2014 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի մարտին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

KRAS codon 12 and 13 mutations ...... herapy trial (N0147 alliance).

@ast

KRAS codon 12 and 13 mutations ...... herapy trial (N0147 alliance).

@en

type

label

KRAS codon 12 and 13 mutations ...... herapy trial (N0147 alliance).

@ast

KRAS codon 12 and 13 mutations ...... herapy trial (N0147 alliance).

@en

prefLabel

KRAS codon 12 and 13 mutations ...... herapy trial (N0147 alliance).

@ast

KRAS codon 12 and 13 mutations ...... herapy trial (N0147 alliance).

@en

P1433

Q33693309-4AB9BF1A-BE65-4FA4-A697-2B5AC13B458A

P1476

Q33693309-9F14794C-276C-45C1-9A45-59ECD116E94D

P2093

Q33693309-28B1FCFB-27E1-467B-B88D-E0BB1E62C7E4

Q33693309-3A6E0164-A3D8-4EC5-8FC2-8063DB2D825A

Q33693309-49A3EFC6-6108-4F6C-96A9-237F6C80A109

Q33693309-7E365F9C-74DC-46AD-B48F-3DE7DF457CD5

Q33693309-7FE2FC2A-1CD2-4D21-96BB-5D41A20E11C0

Q33693309-A479131C-A7D0-4C33-A8CE-2310BCAD9E15

Q33693309-B984B91E-5737-4E3A-A5E3-C8489F8A3A86

Q33693309-C3E65A4C-3512-4DD6-88C6-347BB0CDCC26

Q33693309-E3A4D669-43F5-47C5-A461-25841CA93CB3

Q33693309-E706B842-DC84-4C0F-8E46-B6E730A5B8CB

P2860

Q33693309-09C5E0B4-A8F0-47E9-BBAF-06DE7B0912D6

Q33693309-0A951EE5-2D6A-4F9C-82C7-10D66B74A97D

Q33693309-0AC91D8B-D812-4917-AFD0-FC8F36EED5D3

Q33693309-1147582A-463A-49D5-B1C3-7DEB557AC359

Q33693309-25D80341-47E0-44F2-BF97-82AB0BF6B04F

Q33693309-27A6F57C-74B3-4AFA-BF18-825D494BFF3A

Q33693309-2CF49EAB-4C22-493C-8ADC-C13D6CAFD024

Q33693309-35EA09F4-8D91-4CB6-B2F8-92A19C0A13B8

Q33693309-3C8F3FAB-3459-43B8-8F62-CF37377E5EDC

Q33693309-3E091755-178F-4E19-8C9B-0D389FB0D7F4

P304

Q33693309-8DECF0C3-2EC6-485B-B706-BCB25D612787

P31

Q33693309-9D86419E-284A-4186-8D28-616DE870BB83

P356

Q33693309-B5A8407D-43B6-42D5-87C0-07B3208AFE74

P407

Q33693309-E9C49A9D-44DD-4D5D-8518-65F5734F8990

P433

Q33693309-94759B77-12D5-4AAD-BE8B-11886229A3A0

P478

Q33693309-2C2501BB-2C60-4033-A051-E870292A4AEA

P50

Q33693309-6A0527B4-6AAF-4C92-917F-C638D9B90CA3

Q33693309-ED31E5FE-7D93-4C61-B573-EC8751E3C496

P577

Q33693309-7D44D3B8-1F1D-4B96-8220-AF296DC1F8E1

P5875

Q33693309-98B757EA-B7FB-420E-8D9E-BB207EC9C3F3

P698

Q33693309-99C00CF8-53CD-4802-9D1A-1C5BCF20D639

P921

Q33693309-80E115D0-B378-4888-B8BB-72CC725F6101

P932

Q33693309-AC8F10FB-5D44-4782-95DB-A5F604495534

P356

1078-0432.CCR-13-3140

P1433

Clinical Cancer Research

P1476

KRAS codon 12 and 13 mutations ...... herapy trial (N0147 alliance).

@en

P2093

Alliance for Clinical Trials in Oncology

http://www.w3.org/2001/XMLSchema#string

Frank A Sinicrope

http://www.w3.org/2001/XMLSchema#string

Garth D Nelson

http://www.w3.org/2001/XMLSchema#string

Harry H Yoon

http://www.w3.org/2001/XMLSchema#string

Michelle R Mahoney

http://www.w3.org/2001/XMLSchema#string

Qian Shi

http://www.w3.org/2001/XMLSchema#string

Richard M Goldberg

http://www.w3.org/2001/XMLSchema#string

Stephen N Thibodeau

http://www.w3.org/2001/XMLSchema#string

Steven R Alberts

http://www.w3.org/2001/XMLSchema#string

Suresh G Nair

http://www.w3.org/2001/XMLSchema#string

P2860

Comprehensive molecular characterization of human colon and rectal cancer

KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.

Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab.

Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectum

Colorectal carcinomas with KRAS mutation are associated with distinctive morphological and molecular features

Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer

Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study

KRAS mutation is a predictor of oxaliplatin sensitivity in colon cancer cells

Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status

P304

3033-3043

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-13-3140

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

20

http://www.w3.org/2001/XMLSchema#string

P50

Daniel J. Sargent

P577

2014-03-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

261257258

http://www.w3.org/2001/XMLSchema#string

P698

24687927

http://www.w3.org/2001/XMLSchema#string

P921

P932

4040326

http://www.w3.org/2001/XMLSchema#string